A recent clinical trial revealed that the standard GBM therapy incorporated with the administration of HSPPC-96, as a TLR4 agonist derived from a patient's tumour, potentiated infiltration of CD8+ and CD4+ T cells in the injected tumours and upregulated the immune-related genes [25,26]. This evidence concerns the gene CD8A and neoplasm.